The copy number variation and stroke (CaNVAS) risk and outcome study
AuthorCole, John W.
Akpa, Onoja Matthew
Jimenez Conde, Jordi
Lazcano Dobao, Uxue
Markus, Hugh S.
Soriano Tárraga, Carolina
Stine, O. Colin
Kittner, Steven J.
Mitchell, Braxton D.
PublisherPublic Library of Science
MetadataShow full item record
AbstractBackground and purpose The role of copy number variation (CNV) variation in stroke susceptibility and outcome has yet to be explored. The Copy Number Variation and Stroke (CaNVAS) Risk and Outcome study addresses this knowledge gap. Methods Over 24,500 well-phenotyped IS cases, including IS subtypes, and over 43,500 controls have been identified, all with readily available genotyping on GWAS and exome arrays, with case measures of stroke outcome. To evaluate CNV-associated stroke risk and stroke outcome it is planned to: 1) perform Risk Discovery using several analytic approaches to identify CNVs that are associated with the risk of IS and its subtypes, across the age-, sex- and ethnicity-spectrums; 2) perform Risk Replication and Extension to determine whether the identified stroke-associated CNVs replicate in other ethnically diverse datasets and use biomarker data (e.g. methylation, proteomic, RNA, miRNA, etc.) to evaluate how the identified CNVs exert their effects on stroke risk, and lastly; 3) perform outcome-based Replication and Extension analyses of recent findings demonstrating an inverse relationship between CNV burden and stroke outcome at 3 months (mRS), and then determine the key CNV drivers responsible for these associations using existing biomarker data. Results The results of an initial CNV evaluation of 50 samples from each participating dataset are presented demonstrating that the existing GWAS and exome chip data are excellent for the planned CNV analyses. Further, some samples will require additional considerations for analysis, however such samples can readily be identified, as demonstrated by a sample demonstrating clonal mosaicism. Conclusion The CaNVAS study will cost-effectively leverage the numerous advantages of using existing case-control data sets, exploring the relationships between CNV and IS and its subtypes, and outcome at 3 months, in both men and women, in those of African and European-Caucasian descent, this, across the entire adult-age spectrum.
SponsorsNational Institute of Neurological Disorders and Stroke
KeywordCopy Number Variation and Stroke (CaNVAS) Risk and Outcome study
DNA Copy Number Variations
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15440
Except where otherwise noted, this item's license is described as https://creativecommons.org/publicdomain/zero/1.0/
- The research on association of copy number variation in chromosome 9p21 region with atherothrombotic stroke in the Han Chinese population.
- Authors: Liu H, Yang M, Wang X, Ji Y, Zhao J, Liu W, Zheng J
- Issue date: 2017 Jun 15
- Detecting large copy number variants using exome genotyping arrays in a large Swedish schizophrenia sample.
- Authors: Szatkiewicz JP, Neale BM, O'Dushlaine C, Fromer M, Goldstein JI, Moran JL, Chambert K, Kähler A, Magnusson PK, Hultman CM, Sklar P, Purcell S, McCarroll SA, Sullivan PF
- Issue date: 2013 Nov
- Association between copy number variation losses and alcohol dependence across African American and European American ethnic groups.
- Authors: Ulloa AE, Chen J, Vergara VM, Calhoun V, Liu J
- Issue date: 2014 May
- Genome-wide copy number variation-, validation- and screening study implicates a new copy number polymorphism associated with suicide attempts in major depressive disorder.
- Authors: Rao S, Shi M, Han X, Lam MHB, Chien WT, Zhou K, Liu G, Wing YK, So HC, Waye MMY
- Issue date: 2020 Sep 10
- Copy Number Variation in <i>MUC5AC</i> and Susceptibility to Allergic Rhinitis: A Low-Coverage Whole-Genome Sequencing and Validation Cohort Study.
- Authors: Wang Y, Li L, Yang Y, Feng J, Wang L, Zhang H
- Issue date: 2020 Apr